Global Kidney Cancer Drugs Market

The cancer diagnostics market consists of sales of cancer diagnostic devices and equipment. Cancer diagnostic equipment is used to identify biomarkers, proteins and symptoms in order to detect a cancerous tumor in the patient. Cancer diagnostics market is segmented into companion diagnostics and molecular diagnostics. The cancer diagnostics market covered in this report is segmented by products into companion diagnostics, molecular diagnostics. The cancer diagnostics market is also segmented by end-user into cancer research institutes, diagnostic laboratories, hospitals, others; by method into biopsy, endoscopy, tumor biomarker tests, imaging; by application into cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, others. The global cancer diagnostics market is expected to grow from $156.27 billion in 2020 to $170.21 billion in 2021 at a compound annual growth rate (CAGR) of 8.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer diagnostics market is expected to reach $239.23 billion in 2025 at a CAGR of 8.9%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers is leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving the lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI, developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device specific regulations which include performance standards, premarket data requirements, post market surveillance and labelling requirements associated with their usage. For instance, the labelling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd, GE Healthcare Ltd., and Thermo Fisher Scientific. The regions covered in the cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Others

The antibody-drug conjugates (ADCs) market consists of sales of antibody-drug conjugates. ADCs are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers. The antibody drug conjugates market covered in this report is segmented by type into monoclonal antibodies, linker, drug/toxin, others. The antibody-drug conjugates (ADCs) market is also segmented by application into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others; by product into adcertis, kadcyla, others; by technology into immunogen technology, seattle genetics technology, immunomedics technology, others; by end user into hospital, clinics, others. The global antibody drug conjugates market is expected to grow from $2.34 billion in 2020 to $2.6 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antibody-drug conjugates (ADCs) market is expected to reach $6.12 billion in 2025 at a CAGR of 23.9%. The antibody drug conjugates market is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody drug conjugates driving market growth. The challenges involved in the manufacturing of ADC's is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities require high capital investment and extensive specialized training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibodies manufacturing such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody drug conjugates must be manufactured in aseptic environments and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody drug conjugate trastuzumab deruxtecan (DS-8201). In April 2019, Shanghai Miracogen entered into an agreement with Netherlands based Synaffix to use its tools for building antibody drug conjugates. According to the deal, Miracogen is licensing two platforms from Synaffix which is expected to boost its product pipeline. Manufacturers of antibody drug conjugates are monitored by various regulatory bodies such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance to industry on ADC development and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at FDA such as the Office of Biotechnology Products (OBP)/Office of Pharmaceutical Quality primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). Small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for review of the adequacy of the payload and linker, conjugation reaction and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Immunomedics Inc., and Oxford BioTherapeutics. The regions covered in the antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Others 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Others 3) By Product: Adcertis, Kadcyla, Others 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others 5) By End User: Hospital, Clinics, Others

The conjugated monoclonal antibodies market consists of the sales of conjugated monoclonal antibodies. Conjugated monoclonal antibodies are monoclonal antibodies (MAbs) associated with a chemotherapy drug or a radioactive particle. These are used in the treatment of cancer as they deliver the toxic substance directly to the tumor cells by reducing damage to normal cells in other parts of the body. The conjugated monoclonal antibodies market covered in this report is segmented by drugs into adcetris, kadcyla. The conjugated monoclonal antibodies market is also segmented by technology into cleavable linker, non-cleavable linker and by application into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumour, others. The global conjugated monoclonal antibodies market is expected to grow from $7.98 billion in 2020 to $8.55 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The conjugated monoclonal antibodies market is expected to reach $11.43 billion in 2025 at a CAGR of 8%. The increasing popularity and therapeutic potential of conjugated monoclonal antibodies especially antibody-drug conjugate is expected to drive the conjugated monoclonal antibodies market over the forecast period. Antibody-drug conjugates (ADCs), are class of therapeutics consisting of monoclonal antibodies (MAbs) clubbed with highly potent cytotoxic drugs through a linker to kill the antigen-expressing tumor cells, predominantly used in the treatment of cancer. The U.S. Food and Drug Administration approved only five antibody-drug conjugates drugs from 2000 to 2018 and in 2019, it has approved three antibody-drug conjugates drugs indicating that the increased number of approvals is directly proportional to the use of conjugated monoclonal antibodies mainly in the field of cancer which in turn aids in the growth of the market. The high cost of conjugated monoclonal antibodies is anticipated to limit the growth of the conjugated monoclonal antibodies market. For instance, the cost of the first FDA approved radioimmunotherapy drug Yttrium 90 Ibritumomab Tiuxetan therapeutic (Zevalin) is priced at around $55,000. Moreover, Padcev, an antibody-drug conjugate from Seattle Genetics and Astellas which was approved in December 2019 cost between $110,000 to $120,000 for a course of treatment. The high cost of the therapy makes it unaffordable for the patients and healthcare systems of underdeveloped countries which hinders the growth of the conjugated monoclonal antibodies market. Companies operating in the conjugated monoclonal antibodies market are focusing on strategic collaborations and partnerships for developing new conjugated monoclonal antibodies shaping the market. For instance, in October 2019 NovoCodex, a subsidiary of Zhejiang Medicine Co Ltd collaborated for the second time with Ambrx Inc, a USA-based company engaged in developing protein therapeutics to develop and commercialize Ambrx's internally developed site-specific antibody-drug conjugate, ARX305 used for the treatment of CD70 positive cancers. Following the trend, in June 2020, Monopar Therapeutics, a USA-based biopharmaceutical company, and NorthStar Medical Radioisotopes entered in collaboration to couple Monopar’s MNPR-101 a humanized urokinase plasminogen activator receptor (uPAR) targeted monoclonal antibody in pre-IND stage to a therapeutic radioisotope of NorthStar to create a highly selective agent, which has the potential to kill aberrantly activated cytokine-producing immune cells. In July 2020, AstraZeneca, a UK-based drugmaker has entered into a partnership with Daiichi Sankyo for an amount of $6 billion. This deal is for the global development and commercialization of DS-1062, a TROP2-targeted antibody-drug conjugate (ADC) which is a type of drug that works by using a monoclonal antibody to deliver an attached pharmaceutical payload directly to tumor cells. Daiichi Sankyo is a Japanese based pharmaceutical company engaged in the development of antibody-drug conjugates. Major players in the conjugated monoclonal antibodies market are Pfizer Inc., F. Hoffmann-LA, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., and Spectrum Pharmaceuticals Inc. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global conjugated monoclonal antibodies market is segmented - 1) By Drugs: Adcetris, Kadcyla 2) By Technology: Cleavable Linker, Non-cleavable Linker 3) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour, Others

The monoclonal antibodies (MAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies (MAbs), and other MAbs for human beings and animals. The global monoclonal antibodies (MAbs) market is expected to grow from $106.87 billion in 2020 to $114.43 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $179.56 billion in 2025 at a CAGR of 11.9%. The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs. The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Furthermore, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide. Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth. For instance, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC). Major players in the market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc. The countries covered in the global monoclonal antibodies (MAbs) market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global monoclonal antibodies (MAbs) market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global monoclonal antibodies (MAbs) market is segmented - 1) By Source: Murine, Chimeric, Humanized, Human 2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Others 3) By End Users: Hospitals, Private Clinics, Research Institute

The oncology devices market consists of sales of oncology devices and related services provided by the manufacturer of oncology devices. Oncology is a branch of science that investigates cancer cells. Oncology devices are medical devices used in the diagnosis, management, and treatment of cancer including breast cancer, lung cancer, pancreatic cancer, blood cancer, ovarian cancer, gastric cancer, skin cancer, kidney cancer, and brain tumor. The global oncology devices market is expected to grow from $96.335 billion in 2020 to $110.44 billion in 2021 at a compound annual growth rate (CAGR) of 14.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $196.963 billion in 2025 at a CAGR of 16%. A growing number of cancer cases across the globe is anticipated to boost the demand for the oncology devices market. Cancer is a major health problem across the globe and is the second leading cause of death in the USA. The increasing incidence of cancer is contributing to the surge in the demand for oncology devices to treat cancer patients. The four most common types of cancer globally are prostate, lung, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Therefore, the rise in cancer incidence is anticipated to boost the demand for the oncology drugs market. The low per capita expenditure on healthcare in developing countries is anticipated to limit the growth of the oncology devices market. The per capital expenditure on healthcare is very low in emerging economies such as China, India, and Indonesia as compared to developed nations. For instance, in 2018, the per capita expenditure in the USA was estimated at $10,586, which was much higher than per capita healthcare expenditure in countries such as India - $209, Indonesia - $301, and China - $688. Low per capita healthcare expenditure is a key restraint for the oncology devices market expansion over the forthcoming years. Major companies in the market, research institutes and governments are continuously focusing on developing new devices to treat cancer patients. For instance, AIROS Medical Inc., a medical technology company based in the USA, launched AIROS 6 sequential compression therapy device and garment system to treat breast cancer patients. The advanced technology expanded upper extremity post-mastectomy treatment options for patients with lymphedema. In June 2019, Varian Medical Systems, a US-based company that specializes in radiation oncology treatment and software, announced the acquisition of Endocare, Inc., and Alicon for $185 million. With the acquisition of Endocare Inc. and Alicon, Varian Medical Systems plans to expand its cancer care solutions. Endocare, Inc. is a US-based company that offers systems and disposables for cryoablation and microwave ablation. Alicon is a company based in China and engaged in making embolic therapy for treating liver cancer. The major players covered in the global oncology devices market are Eckert & Ziegler BEBIG, Oncura Inc, GE Healthcare, Medtronic plc, Varian Medical Systems Inc, Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, IBA Group, Biogenex Laboratories, C.R Bard Inc., Theragenics Corporation, PLC. The countries covered in the global oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global oncology devices market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global oncology devices market is segmented - 1) By Device Type: Brachytherapy Devices, Endoscopic Devices 2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radition Therapy 3) By End User: Hospitals, Cancer Research Institutes, Others

The urology medical lasers market consists of sales of urology medical lasers and related services by entities (organizations, sole traders, and partnerships) that manufacture urology medical lasers. Medical lasers are a non-invasive and efficient source of light used to tissue treatment that provides fast healing without discoloration or scarring. Urology medical lasers are used in the treatment of medical conditions related to the urinary system such as urinary stones, benign prostatic hyperplasia (BPH), bladder or prostate cancer, and traumatic injuries. The global urology medical lasers market is expected to grow from $0.871 billion in 2020 to $0.917 billion in 2021 at a compound annual growth rate (CAGR) of 5.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.148 billion in 2025 at a CAGR of 6%. Rising cases of urological disorders contribute to the demand for the urology medical lasers market. Growing urological cases including bladder cancer and prostate diseases among others are boosting the demand for minimally invasive surgeries and related devices. According to the American Institute for Cancer Research’s statistics on bladder statistics, bladder cancer is the sixth most common cancer in men and the 17th most common cancer in women with almost 550,000 new cases in 2018, globally. The surge in urological diseases and conditions increases the demand for urological surgeries and supports the growth of the urology medical lasers market. Low healthcare expenditure in developing economies restrains the urology medical lasers market. The healthcare expenditure in emerging countries is low, limiting access to healthcare facilities. For instance, in 2018, healthcare expenditure as a percentage of gross domestic product (GDP) in Indonesia and India was 3.1% and 3.6% respectively in comparison with 16.9% in the USA. The low healthcare expenditure is likely to limit the growth of the urology medical lasers market in developing economies. Major players operating in the market are continuously focusing on developing new products incorporating advanced technology to meet the requirement of medical professionals. For instance, in June 2020, Olympus Corporation, a Japanese manufacturer of innovative medical and surgical products, launched the Soltive SuperPulsed Thulium Fiber Laser System designed for stone lithotripsy and soft tissue applications in urology. The SuperPulsed thulium fiber laser dust stones into very fine particles and faster than other laser systems. In April 2018, Olympus Corporation, Japan-based manufacturer of innovative technology solutions for medical and surgical procedures, acquired Lithotripsy system design and production technology from Cybersonics, Inc. for an undisclosed amount. The acquisition is expected to help Olympus Corporation to expand manufacturing and enhancing treatment for stone disease and enable the company to improve clinical outcomes, reduce costs, and enhance the quality of life of patients. Cybersonics, Inc. is a USA-based company engaged in designing and developing medical devices that utilize ultrasonic energy. The medical devices developed by the company include high power ultrasonic systems used in the field of neurosurgery, urology, and peripheral vascular surgery. The major players covered in the global urology medical lasers market are Olympus Corporation, Ethicon Inc., Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co. KG, Lumenis Ltd., Becton Dickinson and Company, OmniGuide Holdings Inc., Allengers Medical Systems Limited, CR BARD (BD), Surgical Lasers Inc. , American Medical Systems, Convergent Laser Technologies, Cooltouch, Direx, EDAP TMS, EMS Electro Medical Systems, Gigaa Laser, Hyper Photonics, Jena Surgical, Limmer Laser, LINLINE Medical Systems, LISA laser products, Parto Afarinane Shafa, ProSurg, Quanta System. The countries covered in the global urology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global urology medical lasers market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global urology medical lasers market is segmented - 1) By Laser Type: Holmium Laser System, Diode Laser System, Thulium Laser System, Others 2) By Application: Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC), Others 3) By End User: Hospital, Clinic, Other

The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer. The global cervical cancer diagnostics market is expected to grow from $7.227 billion in 2020 to $7.663 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $9.687 billion in 2025 at a CAGR of 6%. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2018, the United States Preventive Services Task Force has updated its screening guidelines for cervical cancer, which specifies that women between ages 21 to 29 should be screened with a Pap test every 3 years, women between ages 30 to 65 should be screened with any of three tests, namely high-risk HPV testing alone, Pap and high-risk HPV contesting for every 5 years and Pap test alone for every 3 years. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all the kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. For instance, in January 2019, Nurx, a consumer health and telemedicine company, introduced lab testing that allows women to easily and affordably monitor their risk of cervical cancer from the comfort of their home. Similarly, in April 2019, Matter introduced three conceptual cervical cancer examinations through the Sukha project that help women carry out tests at home to break the stigma associated with cervical testing. In November 2018, QIAGEN, a German-based leading supplier of specimen and assay systems for diagnostic techniques, applied testing, academic and pharmaceutical research, collaborated with Self-screen BV and released the QIAscreen HPV PCR Test, a CE-IVD molecular diagnostic test for the detection of 15 recognized high-risk human papillomavirus (HPV) genotypes, which is considered to be the cause of cervical cancer. Self-screen BV is a VU University Medical Centre’s spinoff company based in the Netherlands. The major players covered in the global cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, Zilico, Guided Therapeutics. The countries covered in the global cervical cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The regions covered in the global cervical cancer diagnostics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global cervical cancer diagnostics market is segmented - 1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests 2) By End User: Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres 3) By Age Group: Below 21, Between 21 To 29, Between 30 To 65, Above 65

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, brain tumor, and other different cancer types. The oncology drugs market is segmented into lung cancer; pancreatic cancer; breast cancer; prostate cancer; ovarian cancer; colorectal cancer; gastric cancer; kidney cancer; brain tumor; thyroid cancer; skin cancer; bladder cancer; cervical cancer; blood cancer; and others (kaposi sarcoma, aids-related lymphoma, anal cancer, bone cancer, retinoblastoma, testicular cancer, hepatocellular (liver) cancer, mouth cancer, neuroblastoma). The global oncology drugs market is expected to grow from $80.92 billion in 2020 to $84.38 billion in 2021 at a compound annual growth rate (CAGR) of 4.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $112.14 billion in 2025 at a CAGR of 7%. North America was the largest region in the global oncology drugs market, accounting for 35% of the market in 2020. Asia Pacific was the second largest region, accounting for 35% of the global oncology drugs market. Africa was the smallest region in the global oncology drugs market. The outbreak of the Coronavirus disease (COVID-19) has acted as a significant restraint on the oncology drugs market in 2020 as supply chains were disrupted due to restrictions on trade of pharmaceutical ingredients and products across countries. COVID 19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty in breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and spread globally including Western Europe, North America and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of lockdown and the outbreak is expected to continue to have a negative impact on businesses throughout 2020 and into 2021. Pharmaceutical markets such as this one have been relatively unaffected however due to continued availability of drugs during government lock downs and inelasticity of demand. It is expected that the oncology market will recover from the shock across the forecast period as it is a 'black swan' event and not related to ongoing or fundamental weaknesses in the market or the global economy. Companies in the oncology drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyze large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major oncology drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For example, Johnson and Johnson has recently entered into an agreement with BenevolentAI, a UK-based start-up, to mine data for designing new oncology drugs. Companies in the oncology drug market are investing in targeted therapy, which has proven to be less toxic compared to traditional treatment options. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Companies in oncology market such as Pfizer, Novartis and Abbvie have understood the importance of this treatment method and are increasingly investing in it. According to a report by QuintilesIMS, 87% of the drugs currently in pipeline constitute of targeted therapy drugs. The major players covered in the global oncology drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Gilead Sciences Inc, Bayer AG, Takeda Pharmaceticals. The countries covered in the global oncology drugs market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, Vietnam. The regions covered in the global oncology drugs market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global oncology drugs market is segmented - 1) By Type: Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route Of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs